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A B S T R A C T
Objective: We report the immune response during a case of acute HEV response in a patient with an acute
hepatitis E virus (HEV) genotype 3 infection in the Netherlands.
Methods: Cytokine evaluation was performed via multiplex cytokine array for 65 immune markers in
plasma during the different phases of hepatitis.
Results: The patient initially presented with features typical of acute viral hepatitis, with detectable HEV
RNA in blood. This evolved into a cholestatic disease following peripheral clearance of the virus, leading
to the demise of the patient. Real time PCR revealed the presence of HEV in liver tissue, suggestive of
active intrahepatic infection despite clearance in blood. During the phase of detectable HEV RNA in
serum, there was a surge in T-cell-related immune mediators, as well as interferon alpha and interferon
gamma-induced protein 10 (IP-10), characteristic of a viral infection. After clearance of the virus in the
blood and development of cholestatic hepatitis, several inﬂammatory markers subsided, followed by an
increase in immune factors related to anti-inﬂammatory activity, as well as monocyte/macrophage-
related markers, likely due to the intrahepatic presence of the virus.
Conclusions: This report describes the dissociation of intra- and extra-hepatic immune responses during
acute HEV infection. As shedding of the virus became solely intrahepatic, an immune proﬁle reﬂective of
the activity of hepatic resident cells was observed.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis E virus (HEV), speciﬁcally genotype 3, has been
recognized as a cause of chronic hepatitis in immunosuppressed
individuals, particularly in solid organ transplant recipients in
high-resource countries (Debes et al., 2016; Kamar et al., 2008). In
recent years, some limited insight into the immune modulation
triggered by chronic HEV infection has been obtained. However,
acute symptomatic HEV genotype 3 infection is rare in resource-
rich countries (Brost et al., 2010; Saint-Jacques et al., 2016).
Consequently, there is a paucity of knowledge about the immune
processes involved during acute HEV infection with genotype 3.
This case report describes a patient with fatal autochthonous
cholestatic HEV in the Netherlands, with an analysis of the
patient’s peripheral immune responses.* Corresponding author at: Department of Gastroenterology and Hepatology,
Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Room Na-1011,
3015 CE Rotterdam, The Netherlands.
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A 73-year-old male with a history of diabetes mellitus, presented
with a 2-week history of fatigue and dark urine. His vital signs were
within normal limits and his physical examination was remarkable
for jaundice.
Laboratory investigations showed an aspartate aminotransferase
(AST) level of 4700 IU/ml, alanine aminotransferase (ALT) of 5600 IU/
ml, total bilirubin of 15 mg/dl, alkaline phosphatase of 149 IU/ml,
international normalized ratio (INR) of 1.2, and ferritin level of 19
000 ng/ml. A complete blood count and chemistry panels were
normal. The patient denied taking any new medications, over-the-
counter products, or ingesting mushrooms. He denied the use of
alcohol, cigarettes, or illicit drugs. He had no history of recent travel
and no close contacts reported any recent illnesses.
An infectious work-up revealed negative serology for common
viral hepatitis including hepatitis A, B, and C viruses, Epstein–Barr
virus (EBV), herpes zoster virus (HSV), and cytomegalovirus (CMV).
Serologies for HEV IgG and IgM were positive, and PCR for HEV was
positive at 8.3  104 IU/ml. Further HEV ampliﬁcation determined
the presence of HEV genotype 3. Computed tomography of theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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evidence of portal hypertension. The patient was diagnosed with
acute autochthonous HEV infection. Due to the possible nodular
contour, there was concern for liver cirrhosis in this patient, but a
ﬁbroscan study did not indicate advanced ﬁbrosis.
Following admission, the patient’s liver enzyme levels showed a
downward trend. He showed signs of clinical recovery and was
discharged home with no treatment and a diagnosis of acute
hepatitis E in a recovering phase.
At the patient’s follow-up visit 2 weeks later in the outpatient
clinic, the patient continued to express fatigue. His ALT and AST
levels were 372 IU/ml and 470 IU/ml, respectively, but his total
bilirubin level had increased to 33 mg/dl. The patient was re-
admitted to hospital (for a chronology of events, see Figure 1A).
Repeat PCR for HEV RNA in blood was negative, indicating no
peripheral viral activity (at the time no feces were sent for HEV
assessment). It was decided to obtain a liver biopsy to aid in the
diagnosis, which revealed mild lobular and portal inﬂammatory
inﬁltrates with obvious bilirubinostasis and slight periportal
ﬁbrosis, with no evidence of cirrhosis (Figure 1B). The biopsy
showed no evidence of medication- or toxin-induced liver disease.
A diagnosis of cholestatic hepatitis was made. Over the following
week, the patient developed an upper gastrointestinal bleed
secondary to duodenal ulcers, suffered further hepatic as well as
renal decompensation, and passed away.
Results
To obtain greater insight into the immune processes active during
the acute HEV infection in this patient, a microsphere-based
multiplex protein assay was performed. It was observed that duringFigure 1. (A) Graphic describing the chronological order of presentation, laboratory valu
arrow) and mild lobular (green arrow) inﬂammation; bilirubinostasis (yellow arro
Immunohistochemistry of liver biopsy (J2  40): anti-ds-RNA antibody staining (brownthe acute phase of the HEV infection, expressed by positive HEV RNA
in serum and high levels of transaminases, dramatically increased
levels of all immune analytes were present in the patient as
comparedto two healthycontrols of similarage andsex (Figure2, left
panel). These included elevated T-cell-related cytokines such as
interleukin (IL)-2 and interferon gamma (IFN-g), and monocyte-
derived cytokines such as tumor necrosis factor (TNF), IL-12p70,
IL-18, and macrophage colony-stimulating factor (M-CSF), as well as
markers characteristic of viral infections such as interferon alpha
(IFN-α) and IP-10. These mediators have all been shown to increase
during acute viral hepatitis from different viruses, suggesting no
major differences in initial immune response for HEV compared to
other viral infections (Stacey et al., 2009).
Following negativization of serum HEV RNA and the decrease in
liver transaminases, several markers, including soluble IL-2 receptor
(sIL-2R), IP-10, and eotaxin 3 normalized, as would be expected with
resolution of the viral hepatitis (Figure 2, right panel). However, after
peripheral HEV clearance, a further increase in the T-cell-derived
cytokines IL-2, IFN-g, and IL-10 was observed, likely reﬂecting strong
induction of proinﬂammatory Th1 responses that are counteracted
by the activity of the anti-inﬂammatory cytokine IL-10. Also, the
levelsof IFN-α aswellas importantproinﬂammatorymediators, such
as IL-15, TNF, and IL-1β produced by Kupffer cells, monocytes, and
hepatocytes, remained elevated or were even further augmented.
Despite the absence of detectable HEV RNA in serum, signiﬁcantly
elevated levels of bilirubinwere observed. Surprisingly, examination
of the liver biopsy by HEV RNA PCR demonstrated a positive result
(5.7  105 arbitrary units (AU)). For comparison, we added a negative
biopsy from a chronic HCV patient (<200 copies/g) and a positive
samplefroma patient withacute HEV (6.1  108arbitraryunits(AU)).
Staining of the biopsy with the J2 antibody for double-stranded RNAes, and clinical course. (B) Liver biopsy (hematoxylin–eosin 200): mild portal (blue
ws) and Mallory hyalin in the cytoplasm of hepatocytes (yellow circle). (C)
) in cytoplasmic and perinuclear areas.
Figure 2. Differential levels of immune markers in plasma following changes in HEV RNA levels in blood. Arrows pointing up describe an increase and arrows pointing down
describe a decrease. The left panel describes the fold change compared to controls; the panel on the right describes the fold change after negativization of HEV RNA in blood.
J.D. Debes et al. / International Journal of Infectious Diseases 87 (2019) 39–42 41(ds-RNA) was positive, whereas uninfected control liver was
negative (Figure 1C). These ﬁndings indicate that although HEV
RNA was cleared from blood, the virus was still present and active in
the liver.
Discussion
This case emphasizes the possibility of acute cholestatic viral
hepatitis E due to the presence of intrahepatic HEV RNA with
negative peripheral RNA, which has not been reported before.
Interestingly, during the cholestatic phase and peripheral clear-
ance of HEV in blood, there was an inﬂammatory cascade related to
monocyte/Kupffer cell activation. This clinical manifestation
possibly suggests a response of the intrahepatic component of
the immune system that could have led to the cholestatic pattern
observed. Therefore, one could speculate that while the peripheral
inﬂammatory pattern normalized, an augmented intrahepatic
immune response was observed due to the presence of the virus in
this environment, arguing for a dissociation of intra- and extra-
hepatic immune responses.
This case also highlights potential explanations for the lack of
correlation between HEV RNA detection and HEV IgM levels when
diagnosing acute HEV. The authors of several studies have
reported difﬁculties in diagnosing acute HEV due to individuals
presenting positivity in either one or the other test, but not both.
This has generally been attributed to the lack of standardized PCR
techniques or poor sensitivities of IgM ELISA tests (Debes et al.,
2016; Cattoir et al., 2017). However, as in our patient, a lack ofperipheral blood HEV RNA concomitant with intrahepatic
replication could explain this dissociation and should be kept
in mind in the appropriate clinical setting. Moreover, as HEV can
replicate in the liver without replication in blood (such as in our
patient), in situations where liver biopsy is not possible,
consideration should be given to stool HEV PCR assessment
(which represents shedding from bile) or repetition of HEV IgM.
These tests, if properly applied, could increase the odds of
diagnosis in cases of high suspicion.
Methods
Assessment of levels of cytokines/chemokines
Plasma was collected and multi-analyte proﬁling of cytokines,
chemokines, growth factors, and other proteins was performed
using the Procarta Plex Human Immune Monitoring Panel
(Affymetrix; eBioscience, Vienna, Austria). The panel measured
65 proteins simultaneously (Spaan et al., 2016). The assay was
conducted according to the manufacturer’s instructions, similarly
to our previous studies (Spaan et al., 2016). All samples were
analyzed in one run. Data were analyzed using Procarta Plex
Analyst 1.0.
Liver tissue HEV PCR
RNA was isolated from formalin-ﬁxed parafﬁn-embedded
(FFPE) core needle liver biopsies using the RNA isolation RNAeasy
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negative (chronic HCV) biopsies were included as controls. All
samples were screened for the presence of HEV RNA using
an ISO15189:2012-validated, internally controlled quantitative
real-time RT-PCR, as described previously (Pas et al., 2012).
Immunohistochemical staining for double-stranded RNA
Immunohistochemistry was performed with an automated,
validated, and accredited staining system (Ventana Benchmark
ULTRA; Ventana Medical Systems, Tucson, AZ, USA) using the
Optiview Universal DAB Detection Kit (#760-700). In brief,
following deparafﬁnization and heat-induced antigen retrieval,
the tissue samples were incubated with mouse monoclonal
antibody anti-ds-RNA (J2, English and Scientiﬁc Consulting Kft.)
for 30 min. Incubation was followed by hematoxylin II counter-
staining for 12 min and then blue coloring reagent for 8 min,
according to the manufacturer’s instructions.
Funding
This work was supported by the VIRGO consortium, the Robert
Wood Johnson Foundation (AMFP), American College of Gastro-
enterology, and NIH-NCI grant number R21 CA215883-01A1.
Role of the funding source
None of the funding sources stated had any inﬂuence on the
study design, interpretation of data, or writing of the manuscript.Ethical approval
This study was approved by the Ethics Committee of Erasmus
MC, Rotterdam, the Netherlands.
Conﬂict of interest
No conﬂict of interest declared by any of the authors.
References
Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, et al. Sporadic
cases of acute autochthonous hepatitis E virus infection in Southwest Germany.
J Clin Virol 2010;47:89–92.
Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, et al.
Hepatitis E virus serology and PCR: does the methodology matter?. Arch Virol
2017;38:1062–9.
Debes JD, Pisano MB, Lotto M, Re V. Hepatitis E virus infection in the HIV-positive
patient. J Clin Virol 2016;80:102–6.
Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, et al. Hepatitis E virus
and chronic hepatitis in organ-transplant recipients. N Engl J Med
2008;358:811–7.
Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W, et al. Hepatitis E virus
infection among solid organ transplant recipients, the Netherlands. Emerg
Infect Dis 2012;18:869–72.
Saint-Jacques P, Tissot-Dupont H, Colson P. Autochthonous infection with hepatitis E
virus related to subtype 3a, France: a case report. Ann Hepatol 2016;15:438–41.
Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, Janssen HL, et al. Immunological
analysis during interferon-free therapy for chronic hepatitis C virus infection
reveals modulation of the natural killer cell compartment. J Infect Dis
2016;213:216–23.
Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a
striking systemic cytokine cascade prior to peak viremia in acute human
immunodeﬁciency virus type 1 infection, in contrast to more modest and
delayed responses in acute hepatitis B and C virus infections. J Virol
2009;83:3719–33.
